A recently developed immunoenzymometric assay for activin B has been characterized further by measurement during ovarian stimulation and pregnancy. The assay is based on a monoclonal anti-peptide antibody, anti-β B(101-115) . In addition to quantitative analyses, the antibody has been used for immunohistochemical localization of the activin β B -subunit in human term placenta. Serum samples obtained from patients suffering from tubal factor infertility who were admitted for in-vitro fertilization (IVF) treatment protocols or from patients with proven fertility who were admitted for laparoscopic tubal ligation were collected. The aim was to correlate serum activin B concentrations with other parameters during IVF and with phases of the menstrual cycle. Serum samples obtained from healthy pregnant volunteers were studied to correlate activin B concentrations with clinical parameters. During the IVF treatment protocols, activin B was detectable in all patients studied, and a significant negative correlation was observed between serum activin B and oestradiol concentrations. On the other hand, no significant difference was observed in activin B concentrations when serum samples obtained from patients at different phases of the menstrual cycle were compared, and low concentrations of activin B were observed in the samples obtained from these patients. During pregnancy, a positive correlation was observed between serum activin B concentrations and gestational age. In immunohistochemical analyses of human placental tissue obtained from healthy parturients, the activin β B -subunit was present in trophoblast, amniotic epithelial and Hofbauer cells. The results suggest a potential clinical application in female reproductive medicine for serum activin B measurements.
Introduction
Activins and inhibins are hormones produced mainly by the gonads. Several different molecular forms of these proteins exist, all of which are dimeric, consisting of an α-chain and a β-chain in the case of inhibins, and of two β-chains in the case of activins (for reviews see Ying, 1988; Gaddy-Kurten et al., 1995) . Furthermore, two subgroups of β-chain exist: β A and β B . Based on the structure of the β-chain, two forms of inhibin can be found: inhibin A (αβ A ) and inhibin B (αβ B ). Accordingly, three molecular forms of activin can be found: activin A (β A β A ), activin B (β B β B ) and activin AB (β A β B ). In addition to having stimulatory effects on pituitary gonadotrophin secretion, activins are potentially important paracrine regulators of gonadal function and exert growth factor-like effects on many organs, the most notable of which is that on haematopoietic cells of the bone marrow (Eto et al., 1987) . In addition to the gonads, activin is produced by the human placenta (Petraglia et al., 1991 (Petraglia et al., , 1992 .
The physiological significance of activins and inhibins in humans is not well understood. For clinical purposes, inhibin has been used as a marker for the postoperative follow-up of patients suffering from ovarian granulosa cell tumours (Lappöhn et al., 1989; Burger, 1993; Healy et al., 1993a,b; Slujimer et al., 1993; Jobling, 1994; Cooke et al., 1995) . Almost nothing is known about the physiological significance of activins in humans. A recent study on activin concentrations of samples obtained from female patients at different phases of the menstrual cycle revealed no cycle-specific differences in serum activin concentration (Demura et al., 1993) . One of the greatest problems in understanding the role of activin and inhibin in humans has been the limited availability of reliable immunoassays for inhibin and activin proteins (for a review see Burger, 1993) .
A new sensitive enzyme immunoassay for activin B has been developed recently (Bläuer et al., 1998) . Here we report for the first time the potential use of serum activin B measurements during ovarian stimulation and pregnancy. In addition, an immunohistochemical study has been conducted on the cellular localization of the activin β B -subunit in placental tissue.
Materials and methods

IVF protocol and patients
All patients (n ϭ 9; aged 28-35 years) were suffering from infertility caused by a tubal factor. No patient had unusually high follicle stimulating hormone (FSH) with poor follicular reserves or an unusual luteinizing hormone (LH)/FSH ratio. None had clinically or endocrinologically defined polycystic ovarian disease. Suppression of gonadotrophins was performed using buserelin acetate (0.30 mg four times a day; Suprecur; Hoechst, Frankfurt am Main, Germany) until ovarian suppression was reached (for at least 2 weeks) before treatment with human menopausal gonadotrophin (HMG; starting with 75 IU twice a day i.m.; Humegon; Organon, Oss, The Netherlands). In the case of a poor follicular response, the dose of gonadotrophin was increased to 375 IU/day. Follicular response was monitored with a transvaginal ultrasound scan and by determining serum 17β-oestradiol (Sorin Biomedica Spa, Saluggia, Italy) concentration. Human chorionic gonadotrophin (HCG, Pregnyl; Organon; corresponding to 5000 IU) was injected i.m. when at least two follicles had reached an average diameter of 18 mm (48 h before the scheduled retrieval). Serum oestradiol and progesterone (Kodak Clinical Diagnostics Ltd, Amersham, UK) concentrations were assessed at each appointment. Patients with serum oestradiol concentrations Ͼ4 nmol/l were routinely treated with intravaginal progesterone supplementation (200 mg three times a day; Lugesteron; Leiras, Turku, Finland). Patients with concentrations Ͻ4 nmol/l were treated with i.m. injections of HCG (1500 IU four times a day every third day). After embryo transfer, a potential pregnancy was evaluated by urine HCG screening performed using Delfia ® (Pharmacia-Wallac, Turku, Finland), followed by a transvaginal ultrasound scan for the possible demonstration of an amniotic sac. A serum sample for measuring activin B and steroid concentrations was obtained at each appointment (before and during menopausal gonadotrophin treatment); the last serum sample for these measurements was collected at oocyte retrieval. Correlation analyses of activin B to different clinical parameters were performed, including a correlation to dominant follicle size, total amount of HMG used, number of oocytes and embryos obtained, endometrial thickness and serum steroid content.
Pregnant volunteer selection
For the detection of activin B concentrations during late pregnancy, 30 volunteers with normal pregnancies were selected. After oral consent, a peripheral venous blood sample was obtained from the patients (one sample from each patient), and an ultrasound examination and Doppler evaluation of the well-being and normal morphology of the fetus and placenta were performed. Patient histories were evaluated after delivery, and two patients with complications during delivery or later pregnancy were excluded from the study. Gestational age was estimated based on information on both the last menstrual period and on ultrasound screenings during the second trimester. In the case of a discrepancy between these two data, gestational age was estimated according to the ultrasound scan. Correlation analyses between activin B concentrations and clinical patient data (age of parturient, gestational age at sample collection, duration of pregnancy, weight of placenta, newborn weight) were performed.
Patients at different phases of the menstrual cycle Patients (n ϭ 11; aged 35-45 years) admitted for an endoscopic tubal ligation were asked for oral informed consent. Those who agreed to join the study were questioned about their menstrual history. Only patients showing normal cycle kinetics with no irregularity (cycle duration 26-30 days with 4-7 days of menstrual bleeding) were selected. Those who had had their last menstrual bleeding ഛ11 days earlier were considered to be in the follicular phase, while those who had had their last period Ͼ17 days earlier were considered to be in the luteal phase of the menstrual cycle. All patients had proven fertility, and the age of the patients was between 32 and 45 years. Two samples representing both phases of the cycle were obtained from each patient. Serum progesterone concentrations were determined from each serum sample after an activin B immunoenzymometric assay (IEMA). Patients who had had their menstrual bleeding ഛ11 days earlier and had progesterone concentrations of Ͻ4 nmol/l were considered to be in the follicular phase of the menstrual cycle.
842
Activin B assay
The concentrations of activin B in sera were measured using an IEMA based on a monoclonal antibody raised against a synthetic peptide corresponding to amino acids 101-115 (Mason et al., 1986) of the human β B -subunit (anti-β B ; Bläuer et al., 1998) . Microtitre plates were coated with the antibody (2 µg/ml) by overnight incubation at 4°C. A serum pool containing 100 arbitrary units (U)/ml was used as standard in the absence of a source of purified recombinant activin B. Standard serum (0.1-20 U/ml) and diluted samples were added and incubated for 2 h at 37°C. Biotinylated anti-β B (1 h at 37°C) and horseradish peroxidase (15 min at 21°C) were added. The signal was developed using orthophenylene diamine and hydrogen peroxide. Finally, the absorbance values were read using a spectrophotometer set at a wavelength of 492 nm. The specificity of the assay will be described shortly in detail with regard to cross-reactivity to activin A, inhibin A, and transforming growth factor β 1 . No significant crossreactivity was observed in these analyses. Furthermore, the addition of follistatin or α 2 -macroglobulin did not affect the assay. For all serum measurements, recovery was 90-100% (for a detailed description of these experiments see Bläuer et al., 1998) .
Immunohistochemistry
Immunohistochemical studies were carried out essentially as described previously (Tuohimaa et al., 1993) . Briefly, the formaldehyde-fixed (4% in phosphate-buffered saline) placental tissue samples, after embedding in paraffin, were cut into 5 µm-thick sections and deparaffinated. Endogenous peroxidase activity and non-specific binding sites were blocked as described previously (Bläuer and Tuohimaa, 1995) . Sections were incubated overnight at 4°C with anti-β B (2 µg/ ml) in presence of biotinylated horse anti-mouse immunoglobulin G (1:1000), and thereafter with avidin-biotin-peroxidase complex (ABC kit; Vector Laboratories, Burlingame, CA, USA), both for 30 min. Peroxidase activity was visualized as described previously (Tuohimaa et al., 1993) . Standard second antibody-only and pre-absorption controls were performed.
Statistical analyses
A regression plot was performed for the correlation analyses using the StatView 4.0 ® program. For other comparisons, Student's t-test was used.
Ethical aspects
The study was conducted according to the principles of the Declaration of Helsinki and approved by the ethical committee of Tampere University Hospital, Finland.
Results
The methodological and statistical characteristics of the IEMA are summarized in Figure 1 . The average intra-assay coefficient of variation (CV) for activin B concentrations of 0.1-12.6 U/ ml was 2.3% (range 1.6-3.4%).
The clinical data for the IVF group of patients are shown in Table I . The hormone regimens and follicular response, together with the number of oocytes obtained, and the number of embryos implanted are also indicated. One serum sample was obtained from each patient prior to HMG treatment for endocrine analyses. Subsequently serum samples were collected at each appointment during HMG treatment. The last serum sample was collected at oocyte retrieval. Two pregnancies were achieved in this group of IVF patients. Data The endpoint on the standard serum curve represents the mean of two determinations; on the precision profile it represents the average of eight replicate serum samples. The blank value is shown on the y-axis. The average intra-assay coefficient of variation for activin B concentrations of 0.1-12.6 IU/ml was 2.3% (range 1.6-3.4). The patients were pretreated with a gonadotrophin-releasing hormone agonist (Suprecur). Nine patients were analysed during in-vitro fertilization. dop ϭ date of follicular puncture. Steroid analyses were performed by radioimmunoassay.
from one representative IVF treatment cycle are shown in Figure 2 . Activin B concentrations were compared with all clinical parameters shown in Table II using regression analyses. A statistically significant correlation (P Ͻ 0.05; correlation coefficient 0.4) was only observed between serum activin B and oestradiol concentrations (Figure 3) .
During the menstrual cycle, no significant differences were observed when serum samples obtained from patients at the follicular or luteal phase of the cycle (Table II) were compared. Activin B concentrations were measurable in six of the 11 patients.
The serum concentrations for activin B during late pregnancy are shown in Figure 4 , and related clinical data for the healthy volunteers are shown in Table III . The subjects with measurable serum concentrations of activin B did not differ from the group with non-detectable values when the actual date of The serum samples were obtained from patients with proven fertility undergoing endoscopic tubal ligation. Activin B concentrations were detected by an immunoenzymometric assay. The values are represented as arbitrary units (U) using pooled late pregnancy serum as a reference standard. In four out of 11 patients activin B was not detectable. The difference between the two groups is not statistically significant (P Ͻ 0.2). The phase of the menstrual cycle was determined by information on the last menstrual period and serum progesterone measurements.
confinement, weight of the placenta or newborn birthweight were compared (data not shown). Activin B was detectable in approximately one-third of the patients (10/28). Activin B could not be measured in sera obtained from patients before week 32 of gestation. There was a tendency of increased concentrations towards the end of pregnancy (correlation coefficient 0.4; P Ͻ 0.01). An immunohistochemical analysis was performed on human term placenta using anti-β B as the primary antibody to further elucidate the potential origin of activin B in the pregnant volunteer serum (Figure 5 ). β B -Subunit immunoreactivity was present in trophoblast (Figure 5a ), Hofbauer (Figure 5b ) and amniotic epithelial (Figure 5c ) cells. Pre-absorption (Figure 5d ) and second antibody-only (not shown) controls showed negative staining. . Activin B (arbitrary units using a pooled term pregnancy serum as a reference) and serum 17β-oestradiol concentrations in serum obtained from infertility patients during ovarian stimulation induced by pretreatment with a gonadotrophin-releasing hormone analogue and followed by stimulation by menopausal gonadotrophin. A regression plot analysis is shown (correlation coefficient -0.4; P Ͻ 0.05). Activin concentrations were measured by an immunoenzymometric assay and oestradiol by a radioimmunoassay at each appointment before and during human menopausal gonadotrophin treatment. The last serum sample was collected at oocyte retrieval. Serum activin B was measurable in all patients analysed (n ϭ 9).
Discussion
The results of this study show that: (i) a recently developed IEMA for human activin B is applicable for clinical measurements during late gestation and ovarian stimulation; (ii) activin B, probably originating from the placenta, is detectable in sera of many pregnant women during the last trimester of pregnancy; (iii) during IVF treatment protocols activin B, probably of ovarian origin, shows a negative correlation with serum oestradiol concentrations; and (iv) immunohistochemical analyses of human term placenta reveal the β B -subunit in trophoblast, amniotic epithelial and Hofbauer cells.
Although there are a number of studies on the biochemistry and physiology of activins and inhibins in porcine and ovine species (for a review see Ying, 1988) , limited information is available on the potential use of these molecules in clinical medicine. Inhibin measurements may become a part of clinical practice in the follow-up of ovarian neoplasms (Lappöhn et al., 1989; Burger, 1993; Healy et al., 1993a,b; Slujimer et al., 1993; Jobling et al., 1994; Cooke et al., 1995) . They show potential as a marker during IVF treatment protocols (Reichardt et al., 1993; Yohkaichiya et al., 1993) and may have potential as a prognostic marker during early gestation (Norman et al., 1993; Tovanabutra et al., 1993) . No clear clinical applications for activin B measurements are known to the authors of this study. Measurements of total activin-like activity in serum during the menstrual cycle have been performed but there was Table III ; n ϭ 28). Gestational age is indicated and a regression plot analysis is shown (correlation coefficient 0.4; P Ͻ 0.01). Activin was measured by an immunoenzymometric assay, and gestational age was estimated from the date of the last menstrual period and an ultrasound scan during the second trimester. One serum sample from each patient was collected prior to the ultrasound scan. no cycle-specific fluctuation (Demura et al., 1993) . The results of our study support the probability of no cycle-specific variation in serum activin concentrations in normal healthy female subjects. The site of activin B synthesis in the pregnant volunteers of our study remains to be established. As shown here, and by other investigators (Minami et al., 1992; Rabinovici et al., 1992a) , the β B -subunit can be demonstrated in placental trophoblast cells by immunohistochemical staining. In addition, we were able to demonstrate β B immunoreactivity in Hofbauer cells and amniotic epithelium. Our finding of β B immunoreactivity suggests that amniotic epithelial cells may synthesize the β B -subunit protein. In a previous study (Minami et al., 1992) , Hofbauer cells were shown to express activin A immunoreactivity. Our finding of β B immunoreactivity in these cells suggests that they may be a placental source for other molecules of the inhibin/activin family in addition to activin A.
The presence of activins A, AB and B as well activinbinding protein, follistatin and inhibins in placental tissue has been well established by a number of mRNA (Petraglia et al., 1991 (Petraglia et al., , 1992 (Petraglia et al., , 1993 and immunohistochemical (Minami et al., 1992; Petraglia et al., 1992; Rabinovici et al., 1992a) studies and by reverse phase high performance liquid chromatography (De Kretser et al., 1994) . In addition, the expression of activin receptors II and IIB has been demonstrated on trophoblast cells and fetal membranes (Peng et al., 1993; Petraglia et al., 1994; Shinosaki et al., 1995) . The present immunohistochemical localization of β B immunoreactivity in trophoblast cells in human term placenta is in agreement with the earlier studies. In addition, we were able to demonstrate β B immunoreactivity in Hofbauer and amniotic epithelial cells. In previous studies, preferential expression of the β B -subunit mRNA by 'amnion cells' has been described (Petraglia et al., 1993) , and activin A immunoreactivity has been localized in both amniotic epithelium and Hofbauer cells (Rabinovici et al., 1992a) .
In work performed by Petraglia et al. (1995a,b) , in which a recently developed immunological assay for activin B was applied, measurable concentrations could only be demonstrated in amniotic fluid and cord serum at term, but not in maternal serum. In another more recent study (Woodruff et al., 1996) , serum activin A concentrations clearly increased during late pregnancy showing a pattern resembling that of activin B concentrations during late pregnancy presented here. However, Woodruff et al. (1996) were unable to measure serum activin B concentrations during pregnancy. It appears that in the studies of Petraglia and of Woodruff the same method for serum activin B detection was used. Our findings do not support the view of non-detectable concentrations of maternal serum activin B close to term, and further analyses will be required. These different results may be due to methodological differences, e.g. differences in the epitopes used for antibody production and differential affinities of the antibodies obtained. In the study by Yokonami et al. (1995) , no activin B could be demonstrated in term placenta by Western blotting and high performance liquid chromatography analyses. On the other hand, De Kretser et al. (1994) showed activin B to be present in human term placenta. When compared with the recent findings of Petraglia et al. (1995b) and Woodruff et al. (1996) , one may question the origin of maternal serum activin B demonstrated here. Further analyses will be needed to establish the origin of maternal serum activin B during late pregnancy.
No prior information is available, to our knowledge, on the measurement of activin B during IVF treatment protocols, although there are several reports concerning serum inhibin concentrations during IVF. In our study, activin B concentrations showed a significant correlation only with oestradiol concentration. The molecular mechanisms responsible for the observed correlation are not clear. In human granulosa cell culture experiments and in studies on experimental animals, activin has been shown to exert paracrine effects on ovarian follicle function (for a review see Ying, 1988; Vihko et al., 1993) . In addition, it has been suggested that activin might be important in the induction of atresia (Mather et al., 1992) .
In a study on isolated rat granulosa cells, activin was able to enhance follicle stimulating hormone (FSH)-induced aromatase activity (Miro et al., 1991) . In contrast, in human luteinizing granulosa cells, activin A has been shown to inhibit both basal and FSH-stimulated aromatase activity (Rabinovici et al., 1992b) . The negative correlation between serum oestradiol and activin B concentrations observed here supports the view of an inhibitory effect of activin on human aromatase. It has been shown that activin A is able to inhibit luteinizing hormone-stimulated androgen production by human theca cells .
In summary, a recently developed IEMA for activin B shows clinical potential as a marker during both ovarian stimulation protocols and late gestation. The antibody used for IEMA can also be used for immunohistochemical analyses. Future studies will be conducted on an increased number of patients to confirm the potential of activin B measurements in clinical reproductive medicine.
